The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Expected Market Size Of The Biologics Outsourcing Market In 2026 And How Much Will It Reach By 2030?
The biologics outsourcing market size has seen rapid growth in recent years. It is forecast to expand from $22.58 billion in 2025 to $25.57 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.2%. This historical growth can be attributed to several factors, including increased biologics commercialization activities, the rising capital demands of biologics facilities, the expansion of biosimilar development programs, the increasing complexity of regulatory compliance, and enhanced collaboration between pharmaceutical companies and CDMOs.
The biologics outsourcing market is expected to experience significant expansion in the coming years, with its size projected to reach $42.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. This growth during the forecast period is primarily attributed to the escalating demand for large-scale biologics production, increasing investments in multi-product manufacturing sites, the broadening scope of cell and gene therapy outsourcing, a heightened focus on supply chain resilience, and the increasing adoption of digital manufacturing platforms. Key trends anticipated in the forecast period include a rise in strategic outsourcing for biologic manufacturing, an increasing demand for comprehensive end-to-end outsourcing services, a growing preference for flexible manufacturing partnerships, the expansion of global CDMO networks, and an enhanced focus on optimizing costs and mitigating risks.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12573&type=smp
Which Growth Drivers Are Expected To Support The Biologics Outsourcing Market Forward?
The escalating incidence of cancer is set to propel the growth of the biologics outsourcing market moving forward. Cancer is defined as a wide range of illnesses where abnormal cells multiply uncontrollably in nearly any organ or tissue, extending beyond their normal boundaries and potentially invading adjacent parts or spreading to other organs. Biologics outsourcing plays a pivotal role in managing cancer by providing specific expertise, resources, and infrastructure necessary for the development, manufacturing, and clinical supply of biologic therapies. These therapies encompass monoclonal antibodies, immunotherapies, and other targeted biologics crucial for the diagnosis, treatment, and management of various cancer types. As an illustration, the National Center for Biotechnology Information, a US-based intergovernmental organization, recorded 1,958,310 new cancer cases in the United States in January 2023, with 609,820 cancer deaths projected for 2023. Furthermore, the yearly count of new cancer cases is anticipated to reach 29.5 million and cancer-related fatalities to 16.4 million by 2040. This escalating number of cancer cases is, therefore, a significant driver for the growth of the biologics outsourcing market.
What Key Segment Areas Are Included In The Biologics Outsourcing Market Assessment?
The biologics outsourcing market covered in this report is segmented –
1) By Product Type: Antibodies, Recombinant, Vaccines, Protein, Other Products
2) By Source: Human, Microbial, Other Sources
3) By Application: Oncology, Cellular And Gene Therapy, Blood And Blood-Related Products Development, Vaccine Development, Stem Cell Research, Other Applications
4) By End User: Pharmaceutical Industries, Biotechnology Industries, Contract Development And Manufacturing Organization (CDMO)
Subsegments:
1) By Antibodies: Monoclonal Antibodies, Polyclonal Antibodies
2) By Recombinant: Recombinant Proteins, Recombinant DNA Products
3) By Vaccines: Therapeutic Vaccines, Preventive Vaccines
4) By Protein: Enzymes, Hormones, Cytokines
5) By Other Products: Gene Therapies, Cell Therapies, Biosimilars
Which Trends Are Influencing The Direction Of The Biologics Outsourcing Market?
Major companies within the biologics outsourcing market are strategically focusing on developing new Contract Development and Manufacturing Organizations (CDMOs) to sustain their competitive standing. A CDMO offers pharmaceutical and biotechnology companies a diverse array of services related to the development and manufacturing of drugs and other therapeutic products. As an illustration, in October 2023, Tanvex BioPharma USA Inc., a US-based developer and manufacturer of biopharmaceuticals, launched Tanvex CDMO. This recently introduced division of the company delivers comprehensive, end-to-end services for the development and manufacturing of biologics, addressing the needs of the biopharmaceutical industry. Situated in San Diego’s Sorrento Valley biotech hub, Tanvex CDMO operates a 100,000-square-foot facility that incorporates a state-of-the-art Research and Development (R&D) center, two mammalian Good Manufacturing Practice (GMP) manufacturing suites, one microbial GMP manufacturing suite, Quality Control (QC) laboratories, and a GMP warehouse. Leveraging Tanvex BioPharma USA Inc.’s established track record, Tanvex CDMO aims to support early-stage companies in advancing mammalian and microbial-derived biologics from initial concept to commercialization, thereby providing a significant enhancement to the domain of novel biologics and biosimilars.
Which Organizations Are Involved In The Biologics Outsourcing Market?
Major companies operating in the biologics outsourcing market are AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc., Sartorius Stedim Biotech S.A., Charles River Laboratories International Inc., WuXi Biologics Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., CordenPharma GmbH, Ajinomoto Bio-Pharma Services, Syngene International Limited, Rentschler Biopharma SE, Albany Molecular Research Inc., KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies Inc., Avid Bioservices Inc., BioVectra Inc., ProBioGen AG, ABL Inc., Vibalogics GmbH, JHL Biotech Inc., Goodwin Biotechnology Inc., Crown Bioscience Inc., Cytovance Biologics Inc., LakePharma Inc., AGC Biologics GmbH, Biomay AG, Polpharma Biologics S.A.
Access The Complete Biologics Outsourcing Market Report:
https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report
Which Geographic Region Represents The Largest Biologics Outsourcing Market Share?
North America was the largest region in the biologics outsourcing market in 2025. The regions covered in the biologics outsourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Biologics Outsourcing Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=12573&type=smp
Browse Through More Reports Similar to the Global Biologics Outsourcing Market 2026, By The Business Research Company
Biologics Contract Development Global Market Report 2026
Advanced Therapeutics Pharmaceutical Outsourcing Global Market Report 2026
Medical Device Outsourcing Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/medical-device-outsourcing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
